CL2012002358A1 - Uso de una composicion farmaceutica oral que comprende: i) acido n-[8-(2-hidroxibenzoil)amino] caprilico o una sal del mismo, ii) vitamina b12 y opcionalmente iii) ácido fólico para preparar un medicamento util en el tratamiento de condicionews de deficiencia de vitamina b12. - Google Patents

Uso de una composicion farmaceutica oral que comprende: i) acido n-[8-(2-hidroxibenzoil)amino] caprilico o una sal del mismo, ii) vitamina b12 y opcionalmente iii) ácido fólico para preparar un medicamento util en el tratamiento de condicionews de deficiencia de vitamina b12.

Info

Publication number
CL2012002358A1
CL2012002358A1 CL2012002358A CL2012002358A CL2012002358A1 CL 2012002358 A1 CL2012002358 A1 CL 2012002358A1 CL 2012002358 A CL2012002358 A CL 2012002358A CL 2012002358 A CL2012002358 A CL 2012002358A CL 2012002358 A1 CL2012002358 A1 CL 2012002358A1
Authority
CL
Chile
Prior art keywords
vitamin
acid
hydroxybenzoyl
amino
prepare
Prior art date
Application number
CL2012002358A
Other languages
English (en)
Spanish (es)
Inventor
Cristina Castelli
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of CL2012002358A1 publication Critical patent/CL2012002358A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
CL2012002358A 2010-02-24 2012-08-24 Uso de una composicion farmaceutica oral que comprende: i) acido n-[8-(2-hidroxibenzoil)amino] caprilico o una sal del mismo, ii) vitamina b12 y opcionalmente iii) ácido fólico para preparar un medicamento util en el tratamiento de condicionews de deficiencia de vitamina b12. CL2012002358A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30783610P 2010-02-24 2010-02-24

Publications (1)

Publication Number Publication Date
CL2012002358A1 true CL2012002358A1 (es) 2012-12-14

Family

ID=44477007

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002358A CL2012002358A1 (es) 2010-02-24 2012-08-24 Uso de una composicion farmaceutica oral que comprende: i) acido n-[8-(2-hidroxibenzoil)amino] caprilico o una sal del mismo, ii) vitamina b12 y opcionalmente iii) ácido fólico para preparar un medicamento util en el tratamiento de condicionews de deficiencia de vitamina b12.

Country Status (16)

Country Link
US (3) US20110207693A1 (ja)
EP (2) EP3028709B1 (ja)
JP (3) JP2013520511A (ja)
KR (1) KR20130026429A (ja)
AR (1) AR080292A1 (ja)
AU (1) AU2011220867B2 (ja)
BR (1) BR112012021401B1 (ja)
CA (2) CA2790708A1 (ja)
CL (1) CL2012002358A1 (ja)
CO (1) CO6602160A2 (ja)
HK (1) HK1225609A1 (ja)
MX (1) MX2012009914A (ja)
NZ (2) NZ701274A (ja)
RU (1) RU2576511C2 (ja)
TW (1) TWI590829B (ja)
WO (1) WO2011106378A2 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066375A1 (en) 2011-11-05 2013-05-10 South Alabama Medical Science Foundation Methods, formulations, and kits for rapidly repleting folate levels in women
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN111517980B (zh) * 2020-05-14 2021-02-09 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US6274564B1 (en) * 1996-09-18 2001-08-14 William J. Sarill Compositions of cobalamin and related corrinoids, and uses thereof
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6117868A (en) * 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
ES2386263T3 (es) * 2000-03-21 2012-08-14 Emisphere Technologies, Inc. Método de preparación de salicilamidas alquiladas mediante un producto intermedio de dicarboxilato
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
JP2004526793A (ja) * 2001-04-25 2004-09-02 コバルツ リミテッド 個体における機能性ビタミンｂ１２欠乏症を治療または予防するための方法、およびこの方法に使用するための医療用組成物
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
AU2003275329B2 (en) * 2002-09-13 2008-04-03 Cydex Pharmaceuticals, Inc. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
DE10311089A1 (de) * 2003-03-13 2004-09-23 Roche Diagnostics Gmbh Differenzialdiagnostik und Monitoring von Vitamin B12-, Vitamin B6- und Folsäure-Störungen mittels vier unabhängiger Messgrößen
MXPA06000446A (es) * 2003-07-11 2006-04-07 Novartis Ag Composiciones farmaceuticas de dosis oral que comprenden un agente de distribucion en forma micronizada.
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
EP1773351B1 (en) * 2004-05-06 2019-04-24 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
MX2007001348A (es) * 2004-08-02 2008-03-11 Bebaas Inc Composiciones de vitamina b12.
JP2008509933A (ja) * 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
DK1797127T3 (en) * 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
AU2006312117A1 (en) * 2005-11-04 2007-05-18 Genta Incorporated Pharmaceutical gallium compositions and methods
BRPI0601834A (pt) * 2006-03-30 2007-11-27 Ricardo De Souza Pereira suplementação dietética para curar ou regredir sintomas de refluxo gastroesofágico, gastrite e úlceras
DE102007005952A1 (de) * 2007-02-06 2008-08-07 BSH Bosch und Siemens Hausgeräte GmbH Kältegerät mit an einer Schiene aufgehängten Fachböden
US7943163B2 (en) * 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
ES2443817T3 (es) * 2007-11-02 2014-02-20 Emisphere Technologies, Inc. Método para tratar la deficiencia de vitamina B12

Also Published As

Publication number Publication date
TWI590829B (zh) 2017-07-11
US20110207693A1 (en) 2011-08-25
JP2015193660A (ja) 2015-11-05
EP3028709A1 (en) 2016-06-08
AU2011220867B2 (en) 2014-05-15
MX2012009914A (es) 2013-03-05
RU2012136176A (ru) 2014-03-27
KR20130026429A (ko) 2013-03-13
JP2013520511A (ja) 2013-06-06
JP2017101081A (ja) 2017-06-08
RU2576511C2 (ru) 2016-03-10
WO2011106378A3 (en) 2011-11-24
EP3028709B1 (en) 2019-08-28
CO6602160A2 (es) 2013-01-18
BR112012021401B1 (pt) 2019-12-24
US20200206247A1 (en) 2020-07-02
TW201200139A (en) 2012-01-01
BR112012021401A2 (pt) 2016-10-25
AU2011220867A1 (en) 2012-09-20
CA2996757A1 (en) 2011-09-01
HK1225609A1 (zh) 2017-09-15
US20160074420A1 (en) 2016-03-17
EP2538945A2 (en) 2013-01-02
NZ602032A (en) 2014-11-28
EP2538945A4 (en) 2013-07-24
NZ701274A (en) 2016-03-31
WO2011106378A2 (en) 2011-09-01
CA2790708A1 (en) 2011-09-01
AR080292A1 (es) 2012-03-28

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
NI201500167A (es) Compuestos químicos
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
PH12016502355B1 (en) Pharmaceutical composition
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
MA37400A1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
CL2012002356A1 (es) Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
MX345501B (es) Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
EA201290860A1 (ru) Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
CL2010000434A1 (es) Uso de una composicion farmaceutica que comprende vitamina b12 y acido n-(8-(2-hidroxibenzoil)animo) caprilico o sus sales para preparar un medicamento util en el tratamiento de la deficiencia de vitamina b12; composicion farmaceutica.
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201490599A1 (ru) Соединения триазолопиридина в качестве ингибиторов фосфодиэстеразы pde10a
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
BR112018001035A2 (pt) compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos
CL2012002358A1 (es) Uso de una composicion farmaceutica oral que comprende: i) acido n-[8-(2-hidroxibenzoil)amino] caprilico o una sal del mismo, ii) vitamina b12 y opcionalmente iii) ácido fólico para preparar un medicamento util en el tratamiento de condicionews de deficiencia de vitamina b12.
AR092104A1 (es) LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA)